ArticleCureus2025
The Temporal Trends and Attributed Risk Burden of Kidney Cancer, Bladder Cancer, and Prostate Cancer in China From 1990 to 2021.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The burden of bladder cancer and kidney cancer attributable to smoking in Latin America and the Caribbean from 1990 to 2023 and projections to 2050.Tobacco induced diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo analyze the temporal trends in incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) of kidney, bladder and prostate cancers, and to quantify the attributed risk burden in China from 1990 to 2021.
methodsThe number and age-adjusted rate of incidence (age-standardized incidence rate (ASIR)), prevalence (age-standardized prevalence rate (ASPR)), mortality (age-standardized mortality rate (ASMR)) and DALYs (age-standardized DALY rate (ASDR)) for kidney, bladder and prostate cancers were presented in 2021 along with the change of age-standardized rates (ASRs) in China and globally by age and sex. The average annual percent change (AAPC) was shown and calculated by the Joinpoint regression program. The number of DALYs and ASDR for the three cancers attributed to smoking, high body mass index (BMI), high fasting plasma glucose (HFPG) and occupational exposure to trichloroethylene were presented from 1990 to 2021 by China.
resultsIn 2021, bladder cancer had the highest cases of incidence (1.06×105, 95%UI: 0.83-1.37), mortality (0.45×105, 95%UI: 0.36-0.57) and DALYs (9.30×105, 95%UI: 7.35-11.85), while prostate cancer had the highest prevalence (6.28×105, 95%UI: 4.51-8.53). The largest growth in age-adjusted rate of incidence (ASIR) and prevalence (ASPR) was in prostate cancer, while the largest decrease in DALYs (ASDR) was in bladder cancer. The three cancers mainly occurred in men and elderly over 55 years old. The AAPC of ASIR and ASPR increased for the kidney (1.98, P<0.0001, 2.95, P<0.0001), bladder (0.3, P=0.038, 1.64, P<0.0001) and prostate cancers (2.4, P<0.0001, 3.97, P<0.0001); whilst the AAPC for ASMR and ASDR was insignificant. Finally, the risk burden of smoking, high BMI and HFPG consistently maintained a high level in China from 1990 to 2021.
conclusionThis study describes the latest status and up-to-date burden of kidney, bladder and prostate cancers in China from 1990 to 2021, offering a comprehensive perspective on the policy making and intervention of these cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.